AstraZeneca PLC (AZNCF)
OTCMKTS
· Delayed Price · Currency is USD
130.92
-1.73 (-1.30%)
Dec 23, 2024, 4:00 PM EST
AstraZeneca Revenue
AstraZeneca had revenue of $13.57B in the quarter ending September 30, 2024, with 18.04% growth. This brings the company's revenue in the last twelve months to $51.21B, up 13.81% year-over-year. In the year 2023, AstraZeneca had annual revenue of $45.81B with 3.29% growth.
Revenue (ttm)
51.21B
Revenue Growth
+13.81%
P/S Ratio
n/a
Revenue / Employee
569.59K
Employees
89,900
Market Cap
202.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.66B |
| Ryman Healthcare Limited | 458.44M |
| Verano Holdings Corp. | 897.57M |
| Vireo Growth Inc. | 98.53M |
| Medexus Pharmaceuticals Inc. | 104.76M |
AstraZeneca News
- 1 day ago - AstraZeneca PLC Investors: Please contact the Portnoy Law Firm to recover your losses; February 21, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewsWire
- 1 day ago - AZN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Accesswire
- 1 day ago - AZN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead the AstraZeneca Class Action Lawsuit - GlobeNewsWire
- 1 day ago - EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of AstraZeneca PLC Investors – AZN - Business Wire
- 1 day ago - AstraZeneca gets EU okay for Tagrisso for EGFR lung cancer - Seeking Alpha
- 1 day ago - EU Approves AstraZeneca's (AZN) Tagrisso for Advanced Lung Cancer Treatment - GuruFocus
- 1 day ago - Astra Gets EU Approval for Another Use of Lung Cancer Drug - BNN Bloomberg
- 2 days ago - 4 Ideal Buys From 15 'Safer' Dividends On Bloomberg's 50 December 2025 Watchlist - Seeking Alpha